2021.01.13

FY02/2021 Q3 Results Earnings Release Presentation

2021.01.04

Notification of the commencement of the Phase III clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)

2020.12.07

Notification of the results of Phase Ⅲ clinical study of HP-3150 for “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” in Japan (transdermal, pain treatment NSAID patch)

2020.11.09

Notification of Voluntary Recall for Overseas Pharmaceutical Drug “SALONPAS_®” (2 Patches)

2020.10.08

FY02/2021 Q2 Results Earnings Release Presentation